Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
85 participants
INTERVENTIONAL
2025-05-20
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The patient will use the BiWaze Clear system for their airway clearance therapy, instead of their previously prescribed therapy. BiWaze Clear is an FDA-cleared respiratory therapy for assisting patients in loosening and mobilizing secretions as well as treating and preventing atelectasis by providing lung expansion and high-frequency oscillation therapies, combined with aerosol delivery.
The patient will perform airway clearance with BiWaze Clear as prescribed. The system uses a disposable breathing circuit, which is a single patient use, disposable circuit.
The treatment duration is 6 months . The BiWaze Clear System is indicated for the mobilization of secretions, lung expansion therapy, the treatment and prevention of pulmonary atelectasis and has the ability to provide supplemental oxygen when used with an oxygen supply.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Airway Clearance Technique of Oscillation and Lung Expansion in Bronchiectasis
NCT06393257
Is a Single Daily Session Combining HS + Physio Sufficient to Obtain Long-term Clinical Benefits in Bronchiectasis?
NCT04905992
Airway Clearance and Bronchoalveolar Lavage for Bronchiectasis Patients With Exacerbation
NCT03643302
Breathing Training and Exercise Capacity in Non-CFB
NCT05860803
Oscillating PEP vs Autogenic Drainage in People With Bronchiectasis
NCT03013452
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The BiWaze Clear System is indicated to deliver therapy to adults and children over the age of 5 years in the home care setting. The primary objective of the study is to evaluate the effectiveness of BiWaze Clear therapy in reducing the frequency of pulmonary exacerbations and improving clinical outcomes.
The study will quantify the frequency of pulmonary exacerbations over a 6-month period during BiWaze Clear therapy and compare this data to the number of exacerbations recorded in the 12 months prior to the initiation of therapy.
A total of 85 adult and pediatric male and female patients (5+ years of age) that are diagnosed with Bronchiectasis(BE) will be enrolled into the study.
The patient will perform airway clearance therapy with the BiWaze Clear System. This system is manufactured by ABM Respiratory Care and assists patients in loosening and mobilizing secretions as well as treating and preventing atelectasis by providing lung expansion and high frequency oscillation therapies. The oscillating lung expansion therapy of the BiWaze Clear System is intended to reduce airway obstructions caused by secretions occupying the lower airways, prevent respiratory tract infections, re-expand the collapsed areas of the lung, thereby enhancing gas exchanges and reducing inflammatory response.
BiWaze Clear provides three respiratory therapies: Positive Expiratory Pressure (PEP), Oscillation (OSC), and Nebulize (NEB).
The study will start with screening patients to confirm eligibility before enrollment Day(-7 to-1). At the screening visit, Informed Consent will be discussed and obtained and signed prior to any study procedures. Potential subjects will be screened by inclusion and exclusion criteria, Medical History and respiratory history will be obtained and documented.
At Visit 1 (Day 1), baseline assessment will be performed, including vital signs, respiratory rate , oxygen saturation, measuring height and weight, recording medical and respiratory history, conduct urine pregnancy test for the female that is able to be pregnant. Bronchiectasis symptoms will be collected , Quality of Life-Bronchiectasis questionnaire will be completed, as well as measuring Forced Expiratory Volume( FEV1) and Forced Vital Capacity (FVC).
Biwaze Clear System Device will be dispensed to the patients. Patients will receive their device training. Remote data-captured devices will be dispensed and provided to the patients along with the respective training.
after the base line visit , there will be another 2 onsite visits where the patients should visit their study sites , Visit 2 ( Day 90) and Visit 3 ( day 180). During these 2 visits, patient's weight will be measured and recorded. V ital signs, respiratory rate, and oxygen saturation will be recorded. Quality of Life-Bronchiectasis questionnaire will be completed, as well as measuring Forced Expiratory Volume( FEV1) and Forced Vital Capacity (FVC). All related AEs and SAEs will be recorded , documented and reported as well as Bronchiectasis symptoms will be collected .
In addition of the screening, baseline visits and onsite visits 2 and 3 , a weekly remote data capture devices will record and report the remote monitoring assessments of study endpoints, including vital signs , respiratory rate, and oxygen saturation, Forced Expiratory Volume( FEV1) and Forced Vital Capacity (FVC) and Bronchiectasis symptoms will be recorded. In addition Quality of Life-Bronchiectasis questionnaire will be completed on a monthly basis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
1\. BiWaze Clear System. 2. BiWaze Clear Dual Lumen Breathing Circuit. • Dual Lumen bacterial/viral filter. • Dual Lumen breathing tube. • Patient Interface (Anesthesia mask \[small, medium or large\], Mouthpiece, or trach adapter). 3. Carrying Bag.
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BiWaze Study Device treatment single Arm
All patients will be assigned to a single treatment arm utilizing BiWaze Clear System
BiWaze Clear System
The BiWaze Clear device includes several components as follows:
1. BiWaze Clear System.
2. BiWaze Clear Dual Lumen Breathing Circuit.
* Dual Lumen bacterial/viral filter.
* Dual Lumen breathing tube.
* Patient Interface (Anesthesia mask \[small, medium or large\], Mouthpiece, or trach adapter).
3. Carrying Bag. The patient will perform airway clearance therapy with the BiWaze Clear System
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BiWaze Clear System
The BiWaze Clear device includes several components as follows:
1. BiWaze Clear System.
2. BiWaze Clear Dual Lumen Breathing Circuit.
* Dual Lumen bacterial/viral filter.
* Dual Lumen breathing tube.
* Patient Interface (Anesthesia mask \[small, medium or large\], Mouthpiece, or trach adapter).
3. Carrying Bag. The patient will perform airway clearance therapy with the BiWaze Clear System
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. History of one or more respiratory exacerbations in the past 6 months or two or more respiratory exacerbations in the past 12 months, which required unplanned or unscheduled medical intervention.
3. Ability to perform BiWaze Clear therapy as prescribed.
4. Bronchiectasis diagnosis (including patients with cystic fibrosis with documented bronchiectasis).
5. Signed informed consent (and Child assent if minor subject).
Exclusion Criteria
2. Post bronchodilator FEV₁ ≥ 65 % predicted
3. Anticipated requirement for hospitalization within the next six months.
4. History of pneumothorax within the past 6 months.
5. Use of OLE therapy within the past 12 months.
6. Inability or unwillingness to perform OLE therapy or study procedures as required.
7. Currently enrolled in a different study.
8. Current smoker or tobacco use within the last 30 days.
9. Pregnancy or Breastfeeding.
10. Any medical conditions deemed by investigators to have a significant impact on the study results, e.g., active cancer, severe cardiovascular, severe progressive pulmonary disease, liver, kidney, or neurological conditions.
11. Inability to comply with the treatment protocol or study procedures.
12. Known allergies to materials used in OLE device.
5 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Delve Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central Florida Pulmonary Group, P.A.
Orlando, Florida, United States
Treasure Coast Medical Research Group, LLC
Port Saint Lucie, Florida, United States
Metropolitan Clinical Research
Tamarac, Florida, United States
University of South Florida -Tampa General Hospital
Tampa, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BiWaze Clear_001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.